

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

022567Orig1s000

LABELING

VIIBRYD™ (vilazodone hydrochloride) Tablets

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VIIBRYD™ safely and effectively. See full prescribing information for VIIBRYD.

VIIBRYD (vilazodone HCl) Tablets for oral administration
Initial U.S. Approval: 2011

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

See full prescribing information for complete boxed warning.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders (5.1).
VIIBRYD is not approved for use in pediatric patients (8.4).

INDICATIONS AND USAGE

VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, placebo-controlled trials in adult patients with MDD (1, 14).

DOSAGE AND ADMINISTRATION

- The recommended dose for VIIBRYD is 40 mg once daily (2).
- VIIBRYD should be titrated to the 40 mg dose, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then increased to 40 mg once daily (2).
- VIIBRYD should be taken with food. Administration without food can result in inadequate drug concentrations and may diminish effectiveness (2, 12.3).
- When discontinuing treatment, reduce the dose gradually (2.4).

DOSAGE FORMS AND STRENGTHS

VIIBRYD is available as 10 mg, 20 mg and 40 mg tablets (3).

CONTRAINDICATIONS

- Monoamine Oxidase Inhibitors:** Do not use VIIBRYD concomitantly with an MAOI or within 14 days of stopping or starting an MAOI (4.1).

WARNINGS AND PRECAUTIONS

Clinical Worsening/Suicide Risk: Monitor patients for clinical worsening and suicidal thinking or behavior (5.1).

Serotonin Syndrome or Neuroleptic Malignant (NMS)-like Syndrome: Can occur with treatment. Discontinue and initiate supportive treatment (5.2).

Seizures: Can occur with treatment. Use with caution in patients with a seizure disorder (5.3).

Abnormal Bleeding: Treatment can increase the risk of bleeding. Use with caution in association with nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation (5.4).

Activation of Mania/Hypomania: Can occur with treatment. Screen patients for bipolar disorder (5.5).

Discontinuation of Treatment with VIIBRYD: A gradual reduction in dose is recommended rather than an abrupt cessation (5.6).

Hyponatremia: Can occur in association with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (5.7).

ADVERSE REACTIONS

The most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo) are: diarrhea, nausea, vomiting, and insomnia (6).

To report SUSPECTED ADVERSE REACTIONS, contact Trovis Pharmaceuticals at 1-877-878-7200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

MAOIs: Do not use VIIBRYD concomitantly with an MAOI or within 14 days of stopping or starting an MAOI (4.1, 7.1).

CYP3A4 inhibitors: The VIIBRYD dose should be reduced to 20 mg when co-administered with CYP3A4 strong inhibitors (7.3).

CYP3A4 inducers: Concomitant use of VIIBRYD with inducers of CYP3A4 can result in inadequate drug concentrations and may diminish effectiveness. The effect of CYP3A4 inducers on systemic exposure of vilazodone has not been evaluated (7.3).

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no controlled human data regarding VIIBRYD use during pregnancy. Use only if the potential benefits outweigh the potential risks (2.3, 8.1).

Nursing Mothers: There are no human data regarding VIIBRYD concentrations in breast milk. Women should breast feed only if the potential benefits outweigh the potential risks (8.3, 2.3).

Pediatric Use: The safety and efficacy of VIIBRYD in pediatric patients have not been studied (8.4).

Geriatric Use: No dose adjustment is recommended on the basis of age (8.5).

Hepatic Impairment: No dose adjustment is recommended in patients with mild or moderate hepatic impairment. VIIBRYD has not been studied in patients with severe hepatic impairment (8.6).

Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment. (8.7).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: January 2010

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: <<SUICIDALITY AND ANTIDEPRESSANT DRUGS>>

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
 - 2.1 Initial Treatment of Major Depressive Disorder
 - 2.2 Maintenance/Continuation/Extended Treatment
 - 2.3 Dosing in Special Populations
 - 2.3 Discontinuing Treatment
 - 2.4 Monoamine Oxidase Inhibitors (MAOI)
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
 - 4.1 Monoamine Oxidase Inhibitors
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Clinical Worsening and Suicide Risk
 - 5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions
 - 5.3 Seizures
 - 5.4 Abnormal Bleeding
 - 5.5 Activation of Mania/Hypomania
 - 5.6 Discontinuation of Treatment with VILAZODONE
 - 5.7 Hyponatremia
- 6 ADVERSE REACTIONS**
 - 6.1 Clinical Studies Experience
- 7 DRUG INTERACTIONS**
 - 7.1 Central Nervous System (CNS)-Active Agents
 - 7.2 Drugs that Interfere with Hemostasis (e.g., NSAIDs, aspirin, and warfarin)
 - 7.3 Potential for Other Drugs to Affect Vilazodone
 - 7.4 Potential for Vilazodone to Affect Other Drugs
 - 7.5 Drugs Highly Bound to Plasma Protein

- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Labor and Delivery
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Hepatic Impairment
 - 8.7 Renal Impairment
 - 8.8 Gender Effect
 - 9 DRUG ABUSE AND DEPENDENCE**
 - 9.1 Controlled Substance
 - 9.2 Abuse and Dependence
 - 10 OVERDOSAGE**
 - 10.1 Human Experience
 - 10.2 Management of Overdose
 - 11 DESCRIPTION**
 - 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
 - 13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
 - 14 CLINICAL STUDIES**
 - 16 HOW SUPPLIED/STORAGE AND HANDLING**
 - 16.1 How Supplied
 - 16.2 Storage
 - 17 PATIENT COUNSELING INFORMATION**
 - 17.1 Information for Patients
 - 17.2 Medication Guide
- *Sections or subsections omitted from the full prescribing information are not listed**

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of VIIBRYD or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. VIIBRYD is not approved for use in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4), and Patient Counseling Information (17.1)]

1 INDICATIONS AND USAGE

VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD [see *Clinical Studies* (14)].

Major depressive disorder consists of one or more major depressive episodes. A major depressive episode (DSM-IV-TR) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.

2 DOSAGE AND ADMINISTRATION**2.1 Initial Treatment of Major Depressive Disorder**

The recommended dose for VIIBRYD is 40 mg once daily. VIIBRYD should be titrated, starting with an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then an increase to 40 mg once daily. VIIBRYD should be taken with food. VIIBRYD blood concentrations (AUC) in the fasted state can be decreased by approximately 50% compared to the fed state, and may result in diminished effectiveness in some patients [see *Pharmacokinetics* (12.3)].

2.2 Maintenance/Continuation/Extended Treatment

The efficacy of VIIBRYD has not been systematically studied beyond 8 weeks. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be reassessed periodically to determine the need for maintenance treatment and the appropriate dose for treatment.

2.3 Dosing in Special Populations

Pregnant Women: Neonates exposed to serotonergic antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. When treating pregnant women with VIIBRYD, consider whether the potential benefits outweigh the potential risks of treatment [see *Pregnancy* (8.1)].

Nursing Mothers: There are no clinical data regarding the effect of VIIBRYD on lactation and nursing [see *Nursing Mothers* (8.3)]. Breastfeeding in women treated with VIIBRYD should be considered only if the potential benefit outweighs the potential risk.

Pediatric Patients: The safety and efficacy of VIIBRYD have not been studied in pediatric patients [see *Pediatric Use* (8.4)].

Geriatric Patients: No dose adjustment is recommended on the basis of age [see *Geriatric Use* (8.5)].

Hepatic Impairment: No dose adjustment is recommended in patients with mild or moderate hepatic impairment. VIIBRYD has not been studied in severe hepatic impairment [see *Hepatic Impairment* (8.6)].

Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment. [see *Renal Impairment* (8.7)].

Gender: No dose adjustment is recommended on the basis of gender [see *Gender Effect* (8.8)].

2.4 Discontinuing Treatment

Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as VIIBRYD. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients for these symptoms when discontinuing VIIBRYD. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate [see *Warnings and Precautions* (5.6)].

2.5 Monoamine Oxidase Inhibitors (MAOI)

At least 14 days must elapse between discontinuation of an MAOI and initiation of therapy with VIIBRYD. In addition, at least 14 days must be allowed after stopping VIIBRYD before starting an MAOI [see *Contraindications* (4.1)].

3 DOSAGE FORMS AND STRENGTHS

VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg immediate-release, film-coated tablets.

- 10 mg pink, oval tablet, debossed with 10 on one side
- 20 mg orange, oval tablet, debossed with 20 on one side
- 40 mg blue, oval tablet, debossed with 40 on one side

4 CONTRAINDICATIONS

4.1 Monoamine Oxidase Inhibitors

VIIBRYD must not be used concomitantly in patients taking MAOIs or in patients who have taken MAOIs within the preceding 14 days due to the risk of serious, sometimes fatal, drug interactions with serotonergic drugs. These interactions have been associated with symptoms that include tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features resembling neuroleptic malignant syndrome, seizures, rigidity, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. Allow at least 14 days after stopping VIIBRYD before starting an MAOI [see *Drug Interactions (7.1)*].

5 WARNINGS AND PRECAUTIONS

5.1 Clinical Worsening and Suicide Risk

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in [Table 1](#).

Table 1

Age Range	Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated
	Increases Compared to Placebo
<18	14 additional cases
18-24	5 additional cases
	Decreases Compared to Placebo
25-64	1 fewer case
≥65	6 fewer cases

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see *Warnings and Precautions (5.6)* and *Dosage and Administration (2.4)*].

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.